Reliability and Validity of DIDA-Q in Parkinson's Disease

March 11, 2025 updated by: Marmara University

Validity and Reliability of the Dual Task Impact on Daily Living Questionnaire in Patients with Parkinson's Disease

The aim of our study is to investigate the validity and reliability of the Dual Task Impact on Daily-living Activities (DIDA-Q) to assess the degree of difficulty felt when performing dual tasks during activities of daily living in patients with Parkinson's disease. In our study, the validity and reliability of a questionnaire to assess the degree of difficulty felt while performing dual tasks during activities of daily living in Parkinson's Disease will be examined for the first time. The study will include 95 participants with Hoehn-Yahr Stage 1-3, diagnosed with Idiopathic Parkinson's Disease and able to walk 10 metres without an assistive device.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Dual task ability is defined as the ability to perform two activities simultaneously . It is known that the ability to perform a motor or cognitive secondary activity at the same time during walking (talking to a person next to you while walking or carrying objects while walking) leads to gait and balance problems of different severity depending on the type of secondary task in Parkinson's Disease (PD). When patients with Parkinson's Disease (pwPD) are exposed to dual-task walking, their walking speed and length of stride decrease, and the frequency of freezing phenomena during walking increases. Consequently the risk of falling increase during activities of daily living. Individuals often perform dual tasks while performing activities of daily living because of the nature of the tasks' requirements. Therefore, it has become important to evaluate dual task performance in order to create the right treatment plan in the field of neurological physiotherapy and rehabilitation. Although dual task performance is evaluated with different formulae in the literature, the number of scales evaluating the level of difficulty perceived by the patient during the performance of activities of daily living under dual task is limited. The validity of the existing scales for PD has not been studied. The Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q) is a patient-reported questionnaire developed to assess the degree of difficulty perceived when performing dual tasks during activities of daily living.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
95

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Çapa
      • Istanbul, Çapa, Turkey
        • Istanbul University, Faculty of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who diagnosed with Parkinson's disease were included.

Description

Inclusion Criteria:

  • Diagnosed with Idiopathic Parkinson's Disease according to UK Brain Bank criteria
  • Walking at least 10 metres without an assistive device
  • To have the cognitive capability to understand and answer the questions asked in the scale

Exclusion Criteria:

  • Having any neurological disease other than idiopathic Parkinson's Disease
  • The person has an orthopaedic or cardiopulmonary disease that affects walking
  • Severe hearing-visual impairment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
DIDA-Q
Time Frame: 1 week
Dual Task Impact on Daily-living Activities Questionnaire, higher scores means bad dual task performance
1 week

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Six Spot Step Test cognitive
Time Frame: 1 week
Designed to assess motor-cognitive dual task performance.
1 week
Dual Task Interference
Time Frame: 1 week
It is calculating with a formula which contain single and dual task performance.
1 week
Dual Task Questionnaire
Time Frame: 1 week
patient-reported questionnaire used to measure dual-task performance
1 week
Parkinson Activity Scale
Time Frame: 1 week
a scale to assess patients' mobility and transfers
1 week
Mini-Mental State Examination
Time Frame: 1 week
a short questionnaire giving information about the cognitive status of the patients
1 week
Freezing of Gait Questionnaire
Time Frame: 1 week
a scale questioning the frequency of freezing and freezing qualities in walking
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Marmara University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 13, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 10, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 13, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 11, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 11, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MarmaraU-SANLI-ERSOZ-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings